Navigation Links
Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
Date:3/2/2011

SEATTLE, March 2, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors (GPCRs) linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12). Together with the three previously unlocked orphans linked to squamous cell carcinoma (GPR87), obesity (GPR85) and appetite control (GPR101), Omeros has now successfully unlocked five orphan GPCRs.

GPCRs represent the premier family of drug targets, with more than 30 percent of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros expects to unlock a large percentage of these for drug development. Omeros also announced today that it has cloned approximately 90 percent of the 81 Class A orphan GPCRs into the vector of its proprietary cellular redistribution assay (CRA). The Company is advancing these receptors toward screening in its CRA.

"The progress in our GPCR program has been rapid and we remain on track to screen all of the Class A orphan GPCRs by mid-2012," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Out of the seven receptors screened against only a portion of our compound libraries, we have so far identified multiple small molecules for each of five orphans, demonstrating the power of our proprietary assay to open orphan GPCRs to drug development. We have nearly completed the preparatory steps for large-scale throughput, including generation of clones and constructs as well as integrating our automation capabilities, and we expect that we will soon reach our full screening rate."

Ongoing GPCR Program

Omeros has begun screening orphan GPCRs against its small-molecule chemical libraries using its proprietary, high-throughput CRA. Omeros has announced that it has identified and confirmed s
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger lives ... of the world. As an engineer for the past 20 years, ... of the military service. He,s been to six of the seven ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... Iclaprim also achieved high eradication rates for ... Staphylococcus aureus (MRSA), REINACH, Switzerland, Oct. ... combined results from two pivotal Phase III,clinical ... Antimicrobial Agents,and Chemotherapy (ICAAC)/Infectious Diseases Society of ...
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 data ... aminomethylcycline (AMC). The Phase 2 study compared,safety and ... PTK 0796 to,Zyvox(R) in the treatment of patients ... trial met its primary safety and,tolerability endpoint, demonstrating ...
Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... (PRWEB) November 28, 2014 On Monday, ... and Sendik’s will present Feeding America Eastern Wisconsin with ... Food Market to donate a portion of proceeds to ... Sendik’s promotion, “7 Days, 7 Ways to Save” with ... Fyffes pineapples were two for $4 and Turbana bananas ...
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently ... Dr. Jeffrey Epstein is excited to offer patients ... platform, the site is uniquely designed for easing viewing ... 75% of all prospective rhinoplasty patients research upcoming procedures ... on with smartphones, tablets, and laptops, as well as ...
(Date:11/28/2014)... Written and narrated by award winning author Dr. ... “The Happiest Man In the World: Life Lessons From a ... why Project C.U.R.E. came to be. , Raised in the ... Reverend Richard W. Jackson, Dr. Jackson exceeded his goal of ... that he wasn’t happy. Prompted by this realization, James and ...
(Date:11/28/2014)... November 28, 2014 Not only is ... products free of petroleum, parabens and other cancer-causing agents, ... fund research, education and awareness programs that help in ... and owners have raised an incredible, record-breaking contribution of ... Cure, sales of the Sweet Red Rose Whip Moisturizer ...
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
Breaking Medicine News(10 mins):Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3
... Status Quo of U.S. Health Care,System, According to Deloitte ... 30 More than 750,000,Americans left the country last ... grow to six million by 2010, potentially costing the,U.S. ... in operation,has also soared by 220 percent from just ...
... ABC, NBC ... and CBS, ... adventures of parenting, announced that "Viva la,Familia! de Todobebe" (Hooray for Families! ... night July 25th in Prime,Time delivering 3.3 million viewers 2+ and made ...
... JACKSONVILLE, Fla., July 30 TriServ Alliance recently,submitted ... to support delivery of,health care for the third ... TriServ will begin servicing the 2.9 million active,duty, ... of the,uniformed services, their families and beneficiaries on ...
... Expanded to Include Two ACRO Representatives, WASHINGTON, ... (ACRO) and the Metrics Champion Consortium,(MCC) are pleased ... to the MCC Board of Directors. In an ... the MCC, a multidisciplinary organization,whose mission is to ...
... as a legitimate means of encouraging organisational change ... adversely affect those involved. , Dr Jane ... examined the psychological impact on members of the ... 2004-2006. , She found strikers reported higher ...
... Nonprofit to List of Supported Philanthropies , ... ... www.CollaborateMD.com [CollaborateMD]], a leading provider of on-demand practice management ... for Humanity International], which builds and rehabilitates small houses with ...
Cached Medicine News:Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 2Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 3Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 4Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 5Health News:Todobebe's New Family TV Show Debuts as #1 Show in the U.S. Among All Adults 18 to 34 2Health News:MCC Names ACRO Leaders to Board of Directors 2Health News:Psychological downside to strike action 2Health News:CollaborateMD Becomes a Habitat for Humanity International HopeBuilder 2
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
... is designed for use without ... allowing for full C-Arm access. ... stored onboard when more stability ... quickly slide into standard sockets ...
... The onboard rail clamps ... O.R. tables and stretchers. ... any need for lifting. ... a stable surface combined ...
... The powered torso and ... Orthopedic Trauma Table simultaneously lift ... independent lift mechanism raises and ... for precise positioning. A wide ...
Medicine Products: